2022 has come to a close and we are pleased to share our business update for the end of December.
IsoPet® Therapies:
Marketing – Precision Radionuclide IsoPet® Therapy:
(Mike Korenko, Sc.D • CEO • President – Press Release – January 3, 2023)
Preparation for the Investigational Device Exemption ( IDE ):
VX-2/Tumor Study:
Intellectual Property:
Vivos Inc issued a press release today January 3, 2023 that they filed a provisional patent application on the system equipment to support precision radionuclide therapy.
This includes Shipping Containers, Shielded Vial Holder, a Peltier chiller, and Syringe Shields.
Previously we could only communicate this effort by jeopardizing the patentability. It has been a long substantial effort to streamline all the system devices that IsoPet®/RadioGel™ use, from shipping to therapy.
These devices are integrated into our standardization effort. They can treat tumors ranging from 0.5-gram human lymph nodes to half-pound equine tumors. This equipment was just tested at our equine therapy in NY.
We will make this equipment available to the Mayo Clinic and the therapists in all our current and future regional clinics.
SHIPPING CONTAINER
Eliminated the can and the lead pig containers and designed the shielding of the new plastic container to improve the ease of unpackaging and to ensure that we can ship to White 1 label (UN2910) standards to reduce the FedEx shipping costs and logistics.
SHIELDED VIAL HOLDER
Designed stability in securing the vials while filing the syringes and maximized the vial holder wall thickness to reduce the relatively low radiation further.
PELTIER CHILLER
SYRINGE SHIELD
Dr. Mike Korenko stated “This equipment development occurred over the entire year while incorporating practical experience and feedback from our therapists. We will make this equipment available to the Mayo Clinic for human clinical trials and to the therapists in all our current and future regional clinics.”
Happy New Year.
Mike Korenko, Sc. D
CEO & President Vivos, Inc.
CONTACT:
Vivos Inc.
Michael K. Korenko, Sc.D.
President & CEO